Results from the large international phase 3 ARCHES trial show that, in men with metastatic hormone-sensitive prostate cancer (mHSPC), enzalutamide combined with androgen deprivation therapy (ADT) significantly extended radiographic progression-free survival (rPFS) compared with ADT alone.
Enzalutamide has already demonstrated a benefit in men with metastatic and localised castration-resistant prostate cancer (CRPC), but its efficacy when combined with ADT in mHSPC patients has remained unclear. Executed worldwide at sites in the United States, Canada, Europe, South America, and the Asia-Pacific region, the ARCHES trial was a randomised, double-blind, placebo-controlled, international study that enrolled 1,150 mHSPC patients. Patients treated by ADT (with luteinising hormone-releasing hormone agonist or antagonist, or bilateral orchiectomy) were randomised to either receive a daily dose of 160 mg enzalutamide or placebo.
In the ARCHES study, the enz...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Decision Aids Are Too Difficult for Patients Next Article
No Benefit Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level »
Table of Contents: EAU 2019
Renal Transplantation and Renal Cell Carcinoma
Lower Urinary Tract Symptoms
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.